{
  "docId": "019de076-567f-77cd-b2fe-46fe5b90ebce",
  "docSlug": "f071473f2318bf29da28de95df17ba43",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 31,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights both the clinical urgency and the commercial orphan disease opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-567f-77cd-b2fe-46fe5b90ebce/16",
  "deckHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce",
  "deckJsonHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce.json",
  "deckAnchorHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "list",
      "text": "Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients. ~15,000 new cases per year in the U.S. alone. WHO, CDC, and FDA consider IA a critical priority and a global public health concern.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80690803-1d22-4fe6-85b6-72bfe6eeb3a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.41
      },
      "kind": "list",
      "text": "IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks. Azole use requires significant expertise to manage toxicities and significant drug-drug interactions that often limits duration of use. Resistance to azoles has been increasing globally. Recently, cases of breakthrough IA have been reported in patients receiving antifungal prophylaxis. Failures attributed to non-compliance, poor absorption, DDIs, or infection with a drug-resistant Aspergillus species.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0a84080-ae77-418c-9147-b05ed9e87c7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.69
      },
      "kind": "list",
      "text": "Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only). Rare disease/orphan commercial opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e33585a5-ecb5-4467-9c97-606697b04789",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "* Phase 3 trial dependent on securing partnership(s) or non-dilutive government funds",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d8a4496-7fe3-433f-afbe-e7db6b3baec2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a110096f-32a7-49ba-94f3-56c8969c82c2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e8350fd-f8e5-46e3-b847-1504c590f092",
      "evidence": "The Growing Threat of Invasive Fungal Infections (IFIs) and High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "position": 0,
      "objective": "Highlight the high unmet medical need in treatment of invasive aspergillosis (IA)",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}